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Abstract. Objective and design: We investigated the antino-
ciceptive effect of paracetamol or morphine after repeated 
administration and the changes in the characteristics of cen-
tral µ-, κ- and 5-HT2 receptors.
Treatment: Male rats were injected twice a day for seven 
days with paracetamol (400 mg/kg, i. p.) or morphine (5 mg/
kg, s. c.).
Methods: The antinociceptive effect was evaluated 30 min 
after single and multiple doses of paracetamol and morphine 
through the hot-plate test. Binding techniques were used to 
evaluate the receptor characteristics in the frontal cortex.
Results: Both paracetamol and morphine induced an antino-
ciceptive effect on day 1 but only paracetamol maintained 
this effect for seven days while morphine did not. 
The number of µ-opioid receptors decreased on days 1, 3, 
and 7 by a similar percentage after paracetamol adminis-
tration (by 29, 31 and 34  %, respectively), while morphine 
produced a progressive decrease in comparison with controls 
(by 37, 49 and 60 %, respectively) and κ-opioid receptors 
were unaffected. Both drugs similarly decreased the 5-HT2 
receptor number on all days of treatment (by about 30 %). 
Conclusions: The opioidergic and serotonergic systems are 
involved in different ways in the induction and maintenance 
of antinociception after paracetamol or morphine treatment.
Keywords: Antinociception – Paracetamol – Morphine – 
Brain – µ-, κ- and 5-HT2 receptors.
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Introduction
The central mechanism of action of paracetamol is supported 
by many data both in humans and animals in different pain 
tests and after different routes of administration. The concen-
tration in the central nervous system is dose dependent and 
comparable to that of its antinociceptive effects. Moreover, 
it has been demonstrated that paracetamol is able to cross 
the blood-brain barrier with a homogenous distribution in all 
brain areas [1].
The involvement of prostaglandins (PGs) in the mecha-
nism of action of paracetamol has been proposed, taking 
into account the inhibition of the central cyclo-oxygenases 
(COX-1, COX-2 and COX-3) exerted by this drug [2–6], al-
though the results are controversial in this regard. Moreover, 
interaction with many neurotransmitter systems, in particular 
with the serotonergic system, has been proposed to explain 
the effect of paracetamol: opioidergic, noradrenergic, se-
rotonergic, cholinergic and NO-synthase systems have been 
studied in this regard [7, 8]. Indeed, paracetamol-induced 
antinociception seems to derive from the synergy between 
peripheral, spinal and supraspinal sites [9]. The supraspinal 
components identifi ed in the mechanism of paracetamol are 
opioid-like and serotonergic [10, 11], the former contributing 
less than the latter [7], although the involvement of µ-opioid 
receptors in the antinociceptive action of paracetamol is still 
a matter of debate [12, 13]. We had previously detected an 
increase in serotonin concentration in the cerebral cortex and 
in the pons after acute paracetamol treatment. This effect is 
accompanied by a decrease in the central number of 5-HT2 
receptors [10]. 
It has been shown that the therapeutic activity of some 
non-opioid analgesic drugs can lead to problems of tolerance 
to their antinociceptive effects and it is well known that long-
term administration of morphine produces tolerance to some 
behavioural effects, including analgesia in animals and hu-Correspondence to: M. Sandrini
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mans [14, 15]. The dose of paracetamol used in our present 
and previous works is high, when compared to its therapeutic 
use in humans [6], but its concentration remains below toxic 
levels in rats and mice [16, 17]. Indeed, it has been demon-
strated that these high doses are essential in order to induce 
antinociceptive effects in rodents [18, 19].
A single treatment with paracetamol caused a rapid 
down-regulation of the 5-HT2 receptors, while little or no ev-
idence is present in the literature about the down-regulation 
of µ-receptors. Thus, the aims of the present work were to 
evaluate whether repeated administrations of paracetamol or 
morphine caused the phenomenon of tolerance to their anti-
nociceptive effects in the hot-plate test and to assess possible 
changes in the characteristics of µ-, κ- and 5-HT2 receptors 
in the frontal cortex of rats. 
Materials and methods
Animals
Male Wistar rats, weighing 190–210 g at the beginning of the experi-
ments, were housed in groups of two-three in controlled conditions. The 
ethical guidelines for the investigation of experimental pain in conscious 
animals were followed, and the procedures were carried out according 
to EC ethical regulations for animal research (EC Council 86/609; D.L. 
27/01/1982, No. 116).
Drug treatment
The rats were randomly divided into groups of eight animals. They were 
injected either with paracetamol (400 mg/kg i. p., dissolved in vehicle, 
which consisted of 12.5 % of 1,2-propanediol in sterile saline) or ve-
hicle, or with morphine (5 mg/kg s. c., dissolved in saline) or saline for 
seven consecutive days. The drugs were administered twice a day, at 
8:00 and 18:00. The doses of paracetamol and morphine were chosen 
on the basis of previous dose-response experiments carried out under 
identical experimental conditions [10, 20]. The animals were subjected 
to the hot-plate test 30 min after the fi rst drug administration on days 1, 
3 and 7, each animal only being tested once. On days 1, 3 and 7, dif-
ferent groups of rats (N = 8 per group) were anaesthetised, decapitated 
and their brain removed immediately after pain threshold measurement. 
The frontal cortex was dissected and stored at –80 °C until required for 
analysis. Additional groups of rats were tested for motor activity 30 min 
after the same drug treatment on days 1, 3, and 7 (N = 8 per group). 
Motor activity
Motor activity was measured in an activity cage by means of ultrasound 
apparatus (Cibertec, S.A., Barcelona, Spain). The number of movements 
was recorded continuously between 8:00 and 11:00 a. m. in a soundproof 
room for 10 min, 30 min after drug injection on days 1, 3 and 7. 
Hot-plate test
The hot-plate consisted in an electrically-heated surface (Socrel DS-35, 
Ugo Basile, Comerio, VA, Italy) kept at a constant temperature of 54 ± 
0.4 °C. The latencies for paw licking or jumping were recorded for each 
animal. The analgesic effi cacy of the drug was evaluated as a percentage 
of the maximum possible effect (% MPE), according to the formula (TL-
BL)/(45-BL) × 100, where TL = Test Latency, BL = Baseline Latency, 
45 = cut-off time, in seconds.
Binding assays
The characteristics of µ-receptors were evaluated according to the meth-
od of Hamon and co-workers (1987) [21] with minor modifi cations. 
Aliquots of membrane suspension were mixed with six concentrations 
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Fig. 1. A) The antinociceptive 
action of paracetamol (para: 
400 mg/kg, i. p.) or morphine 
(morp: 5 mg/kg, s. c.) in the hot-
plate test. Values are expressed 
as means ±SEM for 8 rats per 
group. B) [3H]DAMGO and C) 
[3H]ketanserin binding evalua-
tions in the frontal cortex of 
the rat brain: effect of treatment 
with paracetamol or morphine 
thereon. Each value represents 
the mean ±SEM of 8 separate 
experiments. Bmax = maximum 
binding capacity.
*p < 0.05 vs. control.  p < 0.05 
vs. para, same day. ANOVA 
followed by Student-Newman-
Keuls test. 
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of [3H]-D-Ala (2)-Me-Phe (4)-Gly-ol (5)-enkephalin ([3H]DAMGO: 
0.5–10 nM; specifi c activity, 57.5 Ci/mmol) and 1 µM naloxone for the 
determination of non-specifi c binding in a fi nal volume of 0.5 ml. 
The characteristics of κ-receptors were evaluated according to the 
method of Delvin and Shoemaker (1990) [22] with modifi cations. In sat-
uration experiments, DAMGO (1 µM) and DSLET (5 µM) were added 
to each test tube to block µ- and δ-opioid sites. Membrane homogenates 
were added together with 0.25–8 nM [3H]bremazocine (specifi c activity, 
28.0 Ci/mmol) in a fi nal volume of 0.5 ml and incubated at 37 °C for 
45 min. Specifi c binding was determined with bremazocine (10 µM). 
Competition experiments used eight concentrations between 0.1 nM and 
100 µM unlabelled paracetamol to displace 2 nM [3H]bremazocine. 
The characteristics of 5-HT2 binding sites were evaluated according 
to the method of Leysen and co-workers (1982) [23] with minor modifi -
cations, as previously described by our group [10].
Statistical analysis
The results of binding experiments were analysed according to the 
method of Rosenthal. The data were expressed as means ±SEM and cor-
related using analysis of variance (ANOVA) followed by the Student-
Newman-Keuls test. p < 0.05 was considered to be signifi cant.
Drugs 
Paracetamol, morphine, methysergide, naloxone and bremazocine were 
purchased from Sigma Chemicals Co., Milan, Italy. [3H]ketanserin, 
[3H]DAMGO and [3H]bremazocine were obtained from Du Pont NEN, 
Co. Ltd, Milan, Italy. 
Results
Acute treatment with either 400 mg/kg paracetamol or 5 mg/
kg morphine provoked a signifi cant and similar increase in 
the %MPE values. Both drugs maintained the effect also on 
day 3. On day 7, paracetamol had maintained its antinocicep-
tive effect unchanged, while morphine had completely lost 
its effect [total ANOVA: F(8-63) = 19.85; p < 0.001] (Fig. 
1A). 
The motor activity of rats treated with paracetamol or 
morphine was compared with that of control rats on days 
1, 3 and 7. No statistical difference in the total number of 
movements was observed between experimental and control 
groups [control values: 1382 ± 63, 1369 ± 70 and 1348 ± 
78 on days 1, 3 and 7, respectively; total ANOVA F(8-63) = 
0.80, p = 0.608].
In the frontal cortex, on day 1, paracetamol and morphine 
produced a signifi cant and similar decrease in the µ-receptor 
number (Bmax). After morphine treatment, the number of µ-
receptors progressively decreased from day 3 to day 7. Para-
cetamol administration signifi cantly decreased the number of 
µ-receptors at all times: the decrease was approximately the 
same on all study days [ANOVA: F(8-63) = 22.23, p < 0.001] 
(Fig. 1B). The affi nity constants (Kd) remained unchanged 
after any treatment [control values: 0.92 ± 0.09, 1.07 ± 0.11 
and 1.11 ± 0.14 on days 1, 3 and 7, respectively; ANOVA: 
F(8-63) = 1.03, p = 0.476]. 
The characteristics of κ-receptors were not affected by 
paracetamol or morphine at any time of evaluation. Moreo-
ver, paracetamol did not compete with [3H]bremazocine 
binding sites (data not shown). The affi nity constants did not 
change in any group [total ANOVA: Bmax, F(8-63) = 0.24; p 
= 0.982; Kd, F(8-63) = 0.23, p = 0.983] (Table 1). 
As shown in Figure 1C, after acute or repeated adminis-
trations paracetamol and morphine similarly decreased the 
number of 5-HT2 binding sites, the effect being of the same 
order of magnitude on days 1, 3, and 7 [ANOVA: F(8-63) 
= 15.04; p < 0.001]. The affi nity constants (Kd) remained 
unchanged after any treatment [control values: 1.34 ± 0.18, 
1.48 ± 0.07 and 1.28 ± 0.16 on days 1, 3 and 7, respectively; 
ANOVA: F(8-63) = 0.66, p = 0.728].
Discussion
Our data indicate a difference in the effect of paracetamol 
and morphine on non-infl ammatory pain after repeated ad-
ministrations, since morphine lost its analgesic effect while 
paracetamol maintained it, as also described by other authors 
[24]. 
In this experimental model both morphine and paraceta-
mol exerted their analgesic effect without affecting motor 
activity.
Paracetamol decreased the number of µ-receptors in a 
similar way at all evaluation times, while morphine produced 
a time-dependent decrease: this difference may occur as a 
consequence of the low paracetamol affi nity for µ-receptors 
[11] and may partially account for the lack of tolerance in the 
antinociceptive or biochemical effects exerted by this drug 
after 7 days of treatment. 
Neither paracetamol nor morphine modifi ed the charac-
teristics of κ-receptors, suggesting that tolerance to the anal-
gesic effect of morphine does not depend on these receptors. 
Moreover, the 5-HT pathways seem to have little bearing 
on the phenomenon of tolerance, since the 5-HT2 receptor 
change follows the same pattern after repeated administra-
tions with both drugs, while it may be involved in their anti-
nociceptive activity. Indeed, several studies demonstrate that 
systemic morphine exerts its analgesic effect, at least in part, 
through the serotonergic system, increasing the release of se-
rotonin in some brain areas [25] and in synaptosomes of the 
rat cerebral cortex, as do also other µ-opioid agonists [26].
The opioidergic and serotonergic pathways are closely 
interconnected and can interact to modulate and produce 
Table 1. Effect of single or repeated administrations of paracetamol or 
morphine on [3H] bremazocine binding sites in the cerebral cortex of 
the rat.
Treatment Day 1  Day 3  Day 7
Controls Bmax  86.8 ± 7.7 Bmax 71.9 ± 5.6 Bmax 84.7 ± 10.1
 Kd 1.69 ± 0.51 Kd 1.72 ± 0.33 Kd 1.78 ±  0.21
Paracetamol  Bmax 82.4 ± 14.3 Bmax 77.8 ± 10.4 Bmax 73.9 ± 19.4
400 mg/kg Kd 1.87 ± 0.21 Kd 1.92 ± 0.31 Kd 1.80 ±  0.21
Morphine  Bmax 78.4 ± 7.2 Bmax 69.4 ± 5.7 Bmax 77.3 ± 17.3
5 mg/kg Kd 2.01 ± 0.12 Kd 1.64 ± 0.32 Kd 2.03 ±  0.13
Values are means ± SEM of 8 separate experiments. Bmax  (fmol/mg 
prot.) = maximum binding capacity Kd (nM) = equilibrium dissociation 
constant. ANOVA did not reach signifi cance for either parameter.
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many behavioral changes, including nociception (see Mil-
lan, 2002, for a review) [27]. 
The similar effi cacy found in the acute antinociceptive 
effect of these two compounds at the chosen doses under 
our experimental conditions, despite belonging to different 
classes of drugs, may be explained by the fact that both can 
affect either the serotonergic or the opioidergic systems, al-
though at various degrees. On the other hand, the differential 
infl uence of morphine and paracetamol on other transmit-
ters/modulators involved in nociception could explain the 
diverse development of tolerance displayed by these two 
drugs. The involvement of supraspinal neurotransmitter 
systems, accompanying this phenomenon, does not exclude 
other mechanisms, including the interaction between PG me-
tabolism and the serotonergic system [4], or the implication 
of the central cannabinoid system in the antinociceptive ef-
fect of paracetamol [28].
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